Table 1.

Ongoing Clinical Trials of Glutaminase Inhibitor CB-839 in Solid Tumors

clinicaltrials.gov Identifier	Title	Phase
NCT02071862	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors	Phase I (ref. [153])
NCT02771626	Study of CB-839 in Combination With Nivolumab in Patients With Melanoma, ccRCC and NSCLC	Phase I/II
NCT03163667	Study of CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC (ENTRATA Trial)	Randomized Phase II
NCT03428217	Study of CB-839 With Cabozantinib vs. Placebo With Cabozantinib in Patients With Metastatic RCC (CANTATA Trial)	Randomized Phase II